HuidaGene Therapeutics’ CRISPR Therapy Earns Orphan Drug Status for Duchenne Muscular Dystrophy
China-based biotechnology company HuidaGene Therapeutics has announced that it has received Orphan Drug Designation (ODD)...
Pudong New Area Aims to Boost Healthcare with Comprehensive Reform Plan
The General Office of the CPC Central Committee and State Council has released the “Implementation...
AstraZeneca Wins FDA Nod for Airsupra in Asthma Treatment
AstraZeneca (AZ; NASDAQ: AZN), a leading UK pharmaceutical company, announced this week that it has...
Gilead’s Trodelvy Misses Primary Endpoint in Late-Stage NSCLC Trial
Gilead Sciences (NASDAQ: GILD) has announced that a late-stage trial for its antibody-drug conjugate (ADC)...
NHC Unveils Updated Anti-Tumor Drug Guidelines for 2023 with New Drug Additions
The National Health Commission (NHC) has released the “Novel Anti-tumor Drug Clinical Application Guidelines (2023...
Jiangsu Recbio Technology Strikes Licensing Deal with SPIMACO for 9-Valent HPV Vaccine
Jiangsu Recbio Technology Co., Ltd (HKG: 2179), a leading Chinese biotechnology company, has announced a...
Suzhou Jade Biomedical Partners with Hopstem Biotechnology for Cell Therapy Advancements
Suzhou Jade Biomedical Co., Ltd, a prominent player in the Chinese biotech industry, has entered...
Digital Precision Medicine Secures Over $28 Million in Series C Financing
Digital Precision Medicine (DPM), a molecular imaging technology developer incubated by the Chinese Academy of...
NMPA Grants Marketing Approval for Hui Sheng Bio-pharmaceutical’s Janagliflozin
The National Medical Products Administration (NMPA) has granted marketing approval for Hui Sheng Bio-pharmaceutical Co.,...
Novartis Lutathera Combo Therapy Shows Significant Progress in GEP-NETs
Swiss pharmaceutical giant Novartis (NYSE: NVS) has announced preliminary results from a Phase III study...
AstraZeneca’s Imfinzi Meets Primary Endpoint in Hepatocellular Carcinoma Trial
UK pharmaceutical company AstraZeneca (AZ; NASDAQ: AZN) announced the successful completion of the primary endpoint...
J&J’s Balversa Receives Full FDA Approval for Urothelial Carcinoma Treatment
The US Food and Drug Administration (FDA) has converted the 2019 accelerated approval for Johnson...
Shandong Province Launches Initiatives to Accelerate Pharmaceutical Innovation and Growth
Shandong province has announced a comprehensive set of measures aimed at optimizing review and approval...
Everest Medicines Projects Sharp Revenue Increase for 2023 on New Product Launches
Everest Medicines (HKG: 1952), a China-based pharmaceutical company, has announced a preliminary revenue forecast for...
Uni-Bio Science Group Wins NMPA Nod for Generic Forteo Injection for Osteoporosis
Hong Kong-listed biopharmaceutical company Uni-Bio Science Group Ltd (HKG: 0690) has announced that it has...
Endoso Life Raises Over $14 Million in Series A to Expand Endoscope Product Lines
Endoso Life, a developer of high-end medical endoscope systems headquartered in Hangzhou, has reportedly secured...
Convalife Pharmaceuticals and Divamics Inc. Join Forces to Advance Drug Discovery with AI
Convalife Pharmaceuticals, a Shanghai-based clinical pharmaceutical company, and Divamics Inc., a Suzhou-headquartered biopharmaceutical firm specializing...
Sichuan Kelun-Biotech Secures NMPA Nod for Generic Lynparza Equivalent
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd (HKG: 6990), a Chinese pharmaceutical company, has announced that it...
HighTide Therapeutics to Extend NASH Treatment Reach into Hebei Province
HighTide Therapeutics Inc. (HKG: 2511), a China-based non-alcoholic steatohepatitis (NASH) drug developer that recently made...
AI-Driven Biotech Insilico Medicine Teams Up with Hutao Tech for Precision Medicine Robotics
Insilico Medicine, a China-based biotech company driven by generative artificial intelligence (AI), has entered into...